DEKA-1 a dose-finding Phase 1 trial: evaluating safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy.

Disease:

Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer

Study phase:

Phase I

Physician name:

Siqing Fu

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-877-632-6789